4D Molecular Therapeutics, Inc. FDMT
Nov 4, 2026, 9:38 AM EST
- YTD
- +62.27%
- 1 year
- +13.21%
- Market cap
- 672.32M
- Revenue (ttm)
- 17.00K
- EPS (ttm)
- -2.77
- Shares out
- 46.23M
- Forward P/E
- -1.79
- YTD return
- +62.27%
- 1-year return
- +13.21%
- Volume
- 740.40K
- Avg volume
- 1.02M
- Open
- 12.36
- Previous close
- 11.95
- Day's range
- 12.17 – 12.42
- 52-week range
- 6.96 – 16.93
- Analysts
- Buy
- Price target
- 42.64 (+250.3%)
- Earnings date
- Aug 8, 2024
2Y +3.77 (+46.09%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 15989.35
- Price / book
- 0.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -100.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 19.19%
- 50-day average
- 7.82
- 200-day average
- 17.94
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 42.64
- Target (high)
- 82.00
- Strong buy5
- Buy5
- Hold1
- Sell1
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.8309.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.67 | -0.79 | -0.12 | -17.91% |
| Aug 8, 2024 | Jun 1, 2024 | -0.72 | -0.63 | +0.09 | +12.50% |
| Aug 8, 2024 | Jun 1, 2024 | -0.72 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.73 | -0.66 | +0.07 | +9.59% |
| May 9, 2024 | Mar 1, 2024 | -0.73 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.68 | -0.77 | -0.09 | -13.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | B of A Securities | main | Buy | Buy |
| Nov 21, 2024 | Morgan Stanley | init | — | Underweight |
| Nov 14, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | RBC Capital | main | Outperform | Outperform |
| Sep 23, 2024 | Cantor Fitzgerald | down | Overweight | Neutral |
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 4dmoleculartherapeutics.com
News
4DMT to Participate in Upcoming Investor Conferences 
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy 
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target 
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript 
Reviewing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT) 
General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
4DMT Announces New Employment Inducement Grants 
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90
Your note
Sign in to keep a note on FDMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIZILY SCOTT | Officer | Sale | Sep 15, 2024 | 6,781 |
| CHACKO JACOB M | Director | Sale | Apr 20, 2023 | 0 |
| KIM ROBERT YOUNG | Officer | Sale | Feb 4, 2024 | 1,043 |
| KIRN DAVID | Chief Executive Officer | Sale | Jul 9, 2024 | 1,059,150 |
| MORETTI AUGUST J | Chief Financial Officer | Conversion of Exercise of derivative security | May 14, 2023 | 11,045 |
| VIKING GLOBAL INVESTORS LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 3, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 15.97% | 7,382,642 | 43.41M | Sep 29, 2024 |
| RA Capital Management, L.P. | 11.03% | 5,098,211 | 29.98M | Sep 29, 2024 |
| Blackrock Inc. | 10.53% | 4,868,789 | 28.63M | Sep 29, 2024 |
| VR Adviser, LLC | 9.52% | 4,400,000 | 25.87M | Sep 29, 2024 |
| Deep Track Capital, Lp | 8.86% | 4,096,452 | 24.09M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 7.77% | 3,591,030 | 21.12M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.33% | 1,537,368 | 9.04M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.83% | 1,308,552 | 7.69M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.25% | 1,038,505 | 6.11M | Sep 29, 2024 |
| Janus Henderson Global Life Sciences Fund | 2.20% | 1,016,235 | 5.98M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.27% | 589,274 | 3.46M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.10% | 509,965 | 3.00M | Aug 30, 2024 |